Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Safety and Pharmacokinetics (PK)/ Pharmacodynamics (PD) Study to Determine the Dosage of Abraxane in Combination with Phenelzine Sulfate in Metastatic or Inoperable Locally Advanced Breast Cancer

Next Previous
Trial Profile

A Phase Ib Safety and Pharmacokinetics (PK)/ Pharmacodynamics (PD) Study to Determine the Dosage of Abraxane in Combination with Phenelzine Sulfate in Metastatic or Inoperable Locally Advanced Breast Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary) ; Phenelzine (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Proof of concept
  • Acronyms Epi-PRIMED
  • Sponsors EpiAxis Therapeutics

    • Most Recent Events

    • 08 Jun 2022 According to an EpiAxis Therapeutics media release, data published in cancer journal Frontiers of Oncology.
    • 12 Nov 2019 Status changed from recruiting to completed.
    • 01 Dec 2018 According to an EpiAxis Therapeutics media release, the company has expanded this study by including two additional recruitment centres. The two new centers are the Southern Medical Day Care Centre in Wollongong and at the Liverpool Cancer Therapy Centre. The principle investigators at these centre are Professor Phil Clingan and Dr Eugene Moylan, respectively.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top